Adenovirus vector-based SARS-CoV-2 vaccines from immunoinformatics studies to their application in the human population

Visit for more related articles at Research Journal of Congenital Diseases

Abstract

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused coronavirus disease 19 (COVID-19) in China, which was associated with a cluster of respiratory infections. Infection with SARS-CoV-2 has spread to various countries and created a significant threat to public health. Several vaccines have been licensed to protect against infection with SARS-CoV-2.
Recently, the reverse vaccinology technique has been widely used to determine the epitopes for developing multi-epitopic vaccines in various organisms, including Hepatitis B virus, Onchocerca volvulus, Klebsiella pneumonia, Mycobacterium tuberculosis, and Helicobacter pylori. In recent months, reverse vaccinology studies have also been conducted to develop the COVID-19 vaccine. Some researchers using immunoinformatics methods predict S protein epitopes that stimulate the T and B-cell against SARS-CoV-2.
Adenoviral vectors have been studied in a range of infectious diseases as vaccine agents. Their potential to produce a robust and balanced immune response has made them a suitable candidate for the COVID-19 pandemic. These vectors quickly created vaccines with improved designs to overcome the biological difficulties presented by early adenoviral vector systems. This study aimed to discussed Adenovirus vector-based SARS-CoV-2 vaccines from immunoinformatics studies to their application in the human population

Select your language of interest to view the total content in your interested language

Viewing options

Recommended Conferences
Flyer image

Share This Article